Goldman Small Cap Research Issues Research Update and Valuation on Nuvilex, Inc.
(firmenpresse) - BALTIMORE, MD -- (Marketwired) -- 05/28/13 -- Goldman Small Cap Research, a stock market research firm focused on the small cap and microcap sectors, has issued a new research report which provides an updated valuation of Nuvilex Inc. (OTCQB: NVLX), an international firm engaged in live-cell encapsulation technology to treat pancreatic cancer along with the development and study of medical marijuana for use in oncology treatment.
Nuvilex is primarily known for its proprietary, multi-functional, biomedical therapeutic enhancement platform which has been used in clinical trials, notably a Phase 2 pancreatic cancer trial that generated very favorable results. This platform, which essentially serves as an existing therapy booster, is based upon its live-cell encapsulation technology and delivery system and enhances the quality of life.
In the Goldman Opportunity Research report on the Company, analyst Rob Goldman outlines his investment thesis.
"After performing further due diligence on the Company and the oncology treatment space, we felt compelled to raise our valuation Nuvilex. This change is based upon a first-time value for the Company's breast cancer indication and a potential re-valuation of the Company's platform as a result of the recently announced slew of nanobiotechnology industry development deals in oncology that could be worth nearly $1 billion. Word that the Company is gearing up for future trials also played a factor in this valuation increase."
To view Nuvilex reports and articles or to download the report in its entirety, please visit
.
Led by former Piper Jaffray analyst and mutual fund manager Rob Goldman, Goldman Small Cap Research produces small cap and micro cap stock research reports, daily stock market blogs, and popular investment newsletters. For more information, visit .
A Goldman Small Cap Research report is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed. Please read the report's full disclosures and analyst background on our website before investing. Neither Goldman Small Cap Research nor its parent is a registered investment adviser or broker-dealer with FINRA or any other agency. To download our research, view our disclosures, or for more information, visit .
(OTCQB: NVLX): Nuvilex, Inc. has been a provider of all-natural products for many years, has expanded its company to increase its natural product based footprint through medical marijuana studies and is becoming an international biotechnology provider of live, therapeutically valuable, encapsulated cells and services for treatments, research and medicine. The Company's offerings will ultimately include cancer, diabetes and other clinical treatments using the company's natural product knowledge, product base, cell and gene therapy expertise, and live-cell encapsulation technology in addition to other new products currently under development. For more information visit:
Goldman Small Cap Research
Rob Goldman
Analyst
410-609-7100
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 28.05.2013 - 06:30 Uhr
Sprache: Deutsch
News-ID 1231076
Anzahl Zeichen: 0
contact information:
Contact person:
Town:
BALTIMORE, MD
Phone:
Kategorie:
Personal Finance
Anmerkungen:
Diese Pressemitteilung wurde bisher 122 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Goldman Small Cap Research Issues Research Update and Valuation on Nuvilex, Inc.
"
steht unter der journalistisch-redaktionellen Verantwortung von
Goldman Small Cap Research, Inc. (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
